BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction

Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bioph...

November 02, 2023 | News

YS Biopharma Completes Pivotal Phase 3 Enrollment for PIKA Rabies Vaccine Trial

Rabies has an almost 100% fatality rate upon emergence of clinical symptoms. Each year, it claims the lives of approximately 59,000 individuals in ...

November 01, 2023 | News

First Patient Enrolled in Phase III Trial of Boan Biotech's Nivolumab

Nivolumab is a monoclonal antibody that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 (PD-1) receptor...

October 31, 2023 | News

Everest Medicines Receives Approval in Macau for Nefecon® in Primary IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercializ...

October 30, 2023 | News

First Patient Dosed in Europe for Phase 3 Study of Henlius Anti-PD-1 mAb Serplulimab

According to GLOBOCAN 2020, lung cancer (LC) is the second most commonly diagnosed and the first mortality cancer around the world. There were 2.2 million ...

October 26, 2023 | News

PharmaKure submits for Alzheimer's Disease Combined Drug Clinical Trial

PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease and other neurodegenerative diseases...

October 25, 2023 | News

Avance Clinical Briefs 45 Korean Biotechs on Global Drug Development

Dt & SanoMedics Chairman, Charles Park (Park, Chae Gyoo) and Avance Clinical CEO Yvonne Lungershausen co-hosting the Global Clinical Trial Strategy...

October 23, 2023 | News

Regeneron and Sanofi Share Latest on Dupixent® sBLA for Chronic Urticaria

CSU is an inflammatory skin condition, which causes sudden and debilitating hives and swelling on the skin. The CRL states that additional efficacy data ar...

October 23, 2023 | News

Aculys Pharma's Positive Phase 3 Update on Diazepam Nasal Spray for Epileptic Seizures in Japan

These results are from Japan's first domestic Phase 3 clinical trial of an intranasally administered antiepileptic drug for Japanese patients a...

October 19, 2023 | News

Bio4t2 Trials CAR-T for Solid Tumors Without Lymphodepletion

The PrismCore platform generates CAR-T that recognizes overexpressed self-antigens on solid tumors. Bio-Engine adapts the CAR-T to transiently recogni...

October 18, 2023 | News

CANbridge Reaches Full Enrollment in Phase 2 Trial for Gaucher Disease in China

Phase 2 is a randomized, double-blind, dose comparison study to evaluate the efficacy, safety and pharmacokinetics of CAN103 in newly treated GD patients, ...

October 17, 2023 | News

TaiMed Reports Major Advances in Clinical Trials for New HIV Treatment in Taiwan

TaiMed Biologics, an innovation-driven biotech company dedicated to serving unmet healthcare needs, has announced favorable results and the successful comp...

October 17, 2023 | News

Ascentage Pharma & AstraZeneca Collaborate on Phase III Study for CLL/SLL Treatment

The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's B...

October 16, 2023 | News

HanAll, Daewoong, and NurrOn Launch Phase 1 Study for HL192

HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinso...

October 13, 2023 | News

Stay Connected